Precision Medicine Based on Enteric Nervous System Functional Phenotyping

Abstract

Precision medicine is transforming the approach to gastrointestinal (GI) disorders by leveraging individual-specific data for diagnosis and therapy. Recent advances in the functional phenotyping of the enteric nervous system (ENS) provide new avenues for tailoring interventions to the underlying neural and cellular dysfunctions unique to each patient. This review examines the clinical and scientific landscape of ENS-based precision medicine, exploring epidemiology, pathophysiology, phenotyping methods, risk factors, clinical presentations, diagnostic techniques, therapeutic strategies, and emerging advances. Emphasis is placed on the integration of functional phenotyping into clinical workflows, the impact on patient outcomes, and the translation of research findings into practice, offering a comprehensive resource for clinicians and researchers aiming to adopt individualized GI care.

Introduction

The enteric nervous system, often referred to as the "second brain," is a complex network of neurons and glia embedded within the gastrointestinal tract. It regulates essential GI functions, including motility, secretion, and local immune responses. Historically, treatment for GI disorders has followed a "one-size-fits-all" approach, often resulting in suboptimal outcomes. The advent of precision medicine, defined as the customization of healthcare based on individual variability in genes, environment, and lifestyle, is reshaping this paradigm. Functional phenotyping of the ENS, utilizing electrophysiological, molecular, and imaging modalities, provides a foundation for precision interventions targeting specific dysfunctions. This article synthesizes the latest evidence on ENS functional phenotyping and its implications for precision medicine in GI care, with a focus on clinical application and future directions.

Epidemiology / Disease Burden

Disorders of the gut-brain axis, such as irritable bowel syndrome (IBS), functional dyspepsia, gastroparesis, and chronic constipation, represent a significant global health burden. These conditions affect up to 40% of the population at some point in their lives, with substantial impacts on quality of life and healthcare resource utilization. The heterogeneity in clinical presentations and response to therapy highlights the need for individualized approaches. Additionally, neurodevelopmental and neurodegenerative diseases often involve the ENS, further expanding the epidemiological significance of enteric dysfunction. The burden of disease is compounded by diagnostic delays, therapeutic failures, and the psychosocial impact on patients, underscoring the unmet need for precision diagnostics and therapeutics.

Pathophysiology

The pathophysiology of GI disorders encompasses a spectrum of ENS dysfunctions, including altered neuronal excitability, neurotransmitter imbalances, impaired neuro-immune crosstalk, and disrupted glial support. Functional phenotyping has revealed distinct subtypes, such as hyperactive or hypoactive neuronal circuits, aberrant synaptic transmission, and specific neurochemical deficiencies. For example, in IBS, patients may exhibit heightened visceral sensitivity linked to excitatory neurotransmitter dominance, while others show motility disturbances due to reduced cholinergic signaling. Emerging data implicate genetic variants, epigenetic modifications, and environmental factors in modulating ENS function, further supporting the rationale for individualized phenotyping. These mechanistic insights are critical for identifying therapeutic targets and predicting treatment response.

Risk Factors

Risk factors for ENS dysfunction and related GI disorders are multifactorial. Genetic predisposition, early-life stressors, infections, antibiotic exposure, and gut microbiota alterations have all been implicated. Notably, mutations in genes encoding ion channels, neurotransmitter receptors, and neurotrophic factors can predispose to specific phenotypes of enteric neuropathy. Environmental triggers, such as diet, stress, and toxins, interact with genetic background to modulate ENS integrity. Moreover, systemic diseases like diabetes mellitus, Parkinson’s disease, and autoimmune conditions frequently involve secondary ENS dysfunction. Comprehensive risk stratification, incorporating clinical, genetic, and environmental data, is essential for the precision medicine model.

Clinical Features

ENS dysfunction manifests as a broad spectrum of GI symptoms, including abdominal pain, bloating, altered bowel habits, nausea, vomiting, and dysphagia. The heterogeneity of clinical presentations reflects the diversity of underlying neural phenotypes. For instance, some patients with hypersensitive ENS phenotypes present with severe pain despite minimal structural abnormalities, while others with hypoactive neuronal circuits experience profound motility disturbances. Non-motor symptoms, such as fatigue and anxiety, are also common, reflecting the bidirectional communication between the ENS and central nervous system. Careful clinical phenotyping, including symptom diaries and validated questionnaires, is integral to guiding further diagnostic and therapeutic interventions.

Diagnosis

Diagnostic evaluation of ENS disorders has evolved from exclusion-based approaches to mechanistically driven assessments. Functional phenotyping employs a combination of high-resolution manometry, electrogastrography, mucosal biopsies with immunohistochemistry, and advanced neuroimaging techniques such as functional MRI and PET. Molecular profiling, including transcriptomic and proteomic analyses of enteric neurons, provides additional layers of diagnostic precision. Non-invasive biomarkers, such as serum neuropeptides and fecal microbiome signatures, are increasingly utilized in research and clinical trials. Integration of these tools into clinical practice enables the identification of distinct ENS functional subtypes, paving the way for targeted therapy.

Treatment & Management

Traditional management of GI disorders has relied on empirical pharmacotherapy and symptomatic relief. Precision medicine, informed by ENS functional phenotyping, allows for mechanism-based interventions. For example, patients with cholinergic deficits may benefit from prokinetic agents targeting muscarinic receptors, while those with hyperexcitability may respond to neuromodulators or targeted neurotoxins. Neuromodulation techniques, such as sacral nerve stimulation and gastric electrical stimulation, are tailored based on electrophysiological findings. Dietary interventions and microbiome modulation are considered in patients with identified dysbiosis. Multidisciplinary care, involving gastroenterologists, neurologists, dietitians, and psychologists, remains essential for holistic management.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of novel therapies targeting ENS dysfunction at the molecular and cellular levels. Stem cell-based regenerative approaches aim to restore lost or dysfunctional enteric neurons. Gene editing technologies offer the potential to correct monogenic ENS disorders. Personalized microbiome therapeutics, including fecal transplantation and designer probiotics, are under investigation. Advanced neuroimaging and wearable biosensors facilitate real-time monitoring of ENS function, allowing for dynamic treatment adjustments. Artificial intelligence and machine learning algorithms are being developed to predict treatment response and optimize personalized care pathways. These innovations promise to further refine the precision medicine paradigm in GI practice.

Guideline Recommendations

Current clinical guidelines increasingly recognize the value of individualized approaches in the management of GI disorders. The Rome Foundation and leading gastroenterology societies advocate for symptom-based phenotyping and the use of targeted therapies guided by functional assessments. However, widespread adoption of ENS functional phenotyping in routine practice is limited by access to specialized testing, cost considerations, and the need for standardized protocols. Ongoing research and consensus-building are crucial to translating emerging evidence into actionable clinical guidelines, ensuring equitable access to precision diagnostics and therapeutics.

Conclusion

Functional phenotyping of the enteric nervous system represents a pivotal advancement in the evolution of precision medicine for gastrointestinal disorders. By elucidating patient-specific neural dysfunctions, this approach enables tailored therapy, improved outcomes, and reduced healthcare burden. The integration of advanced diagnostics, mechanism-based interventions, and multidisciplinary care is key to realizing the full potential of ENS-based precision medicine. Continued research, innovation, and guideline development will be essential to overcoming current barriers and expanding the reach of personalized GI care.